Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders - Engineering National Academies of Sciences  and Medicine,  Health and Medicine Division,  Board on Health Sciences Policy,  Forum on Neuroscience and Nervous System Disorders

Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders

Proceedings of a Workshop
Buch | Softcover
96 Seiten
2022
National Academies Press (Verlag)
978-0-309-69137-6 (ISBN)
17,45 inkl. MwSt
Psychiatric illnesses - such as major depressive disorder, anxiety disorder, substance use disorder, and posttraumatic stress disorder (PTSD) - are widely prevalent and represent a substantial health burden worldwide. Yet, conventional medications for mental illnesses often fail to provide relief to patients' disruptive and disabling symptoms. Existing and emerging evidence that psychedelics (e.g., LSD and psilocybin) and entactogens (e.g., MDMA) may be useful as tools to alleviate mental illness has sparked a renaissance of interest by investigators, clinicians, drug developers, and patient advocates in recent years. While promising data on therapeutic efficacy has energized research and development, resolving the mechanisms of action will be important for optimizing the efficacy and safety of these medicines. Further, evaluating the effect of psychedelics and entactogens on mood and behavior comes with unique challenges still in need of resolution. These include unresolved questions relating to blinding, placebo and nocebo effects, and the impact of psychosocial contexts.


In response to this renewed interest, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders convened a workshop on March 29-30, 2022. The workshop brought together a diverse group of stakeholders to explore the use of psychedelics and entactogens as treatments for psychiatric disorders. This Proceedings of a Workshop summarizes the presentations and discussions of the workshop.


Table of Contents


Front Matter
1 Introduction and Background
2 History and Current Status of Psychedelics and Entactogens for
the Treatment of Psychiatric Disorders
3 Mechanisms of Action and Key Research Gaps for Psychedelics and
Entactogens
4 Advancing Clinical Development: Challenges and Opportunities
5 Anticipating Implementation to Guide Clinical Research and
Development
6 Reflecting on the Road Ahead
Appendix A: References
Appendix B: Workshop Agenda
Erscheinungsdatum
Verlagsort Washington
Sprache englisch
Maße 152 x 229 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Neurologie
ISBN-10 0-309-69137-0 / 0309691370
ISBN-13 978-0-309-69137-6 / 9780309691376
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
interdisziplinäre Diagnose- und Behandlungsstrategien

von Christoph Maier; Ulrike Bingel; Esther Pogatzki-Zahn

Buch | Hardcover (2024)
Urban & Fischer in Elsevier (Verlag)
97,00